Home

AlzProtect is a biopharmaceutical company discovering and developing drug candidates, for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) and orphan tauopathies such as Progressive Supranuclear Palsy (PSP).

Our lead compound, AZP2006, is currently in clinical phase 1

Multiple ascending dose study in healthy volunteers is ongoing. These studies show that AZP2006 was well tolerated.

AZP2006

Read more

Targeted therapeutical areas

Read more

AlzProtect, planning its entry into phase 2, appoints Noëlle CALLIZOT as director of...

March, 26 2018 Read more

AlzProtect raises 14 million euros with the entry of Xerys to launch phase II of its drug for the...

January, 22 2018 Read more